Clinical trials in Madrid – page 208

3 294 clinical trials in Madrid, Spain across 24 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in SpainEnsayosClinicos.es

Madrid at a glance

3 294

clinical trials

Research sites24

Quick filters

3 294 trials in Madrid

Open in trial search

Multiple sclerosis+1

Not recruiting

Study on B-Cell Levels in Infants Exposed to Ocrelizumab During Pregnancy for Mothers with Multiple Sclerosis or Clinically Isolated Syndrome

Registered drugNo placebo

Study on B-Cell Levels in Infants Exposed to Ocrelizumab During Pregnancy for Mothers with Multiple Sclerosis or Clinically Isolated Syndrome

Registered drugNo placebo

Spain

Participants:18–64 years
Substances:Ocrelizumab
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Splenic marginal zone lymphoma

Not recruiting

Study Comparing Rituximab and Zanubrutinib with Rituximab Alone for Untreated Patients with Splenic Marginal Zone Lymphoma

Registered drugNo placebo

Study Comparing Rituximab and Zanubrutinib with Rituximab Alone for Untreated Patients with Splenic Marginal Zone Lymphoma

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Rituximab
Sponsor:Association International Extranodal Lymphoma Study Group (IELSG)

Contact Research Centre

Non-small cell lung cancer

Not recruiting

Study of Farletuzumab Ecteribulin for Patients with Metastatic Non-Small Cell Lung Cancer After Previous Treatments

InvestigationalNo placebo

Study of Farletuzumab Ecteribulin for Patients with Metastatic Non-Small Cell Lung Cancer After Previous Treatments

InvestigationalNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Farletuzumab Ecteribulin
Sponsor:Bristol Myers Squibb International Corporation

Contact Research Centre

Breast cancer+2

Not recruiting

Study of Tucatinib, Trastuzumab, and Pertuzumab for Patients with Advanced or Metastatic HER2+ Breast Cancer

Registered drug

Study of Tucatinib, Trastuzumab, and Pertuzumab for Patients with Advanced or Metastatic HER2+ Breast Cancer

Registered drug

Spain

Participants:18–64 years · 65+ years
Substances:Pertuzumab
Sponsor:Seagen Inc.

Contact Research Centre

Alpha-1 antitrypsin deficiency+1

Not recruiting

Study Comparing INBRX-101 and Human Alpha1-Proteinase Inhibitor for Adults with Alpha-1 Antitrypsin Deficiency Emphysema

Registered drug

Study Comparing INBRX-101 and Human Alpha1-Proteinase Inhibitor for Adults with Alpha-1 Antitrypsin Deficiency Emphysema

Registered drug

Spain

Participants:18–64 years · 65+ years
Substances:Human Alpha-1-Proteinase Inhibitor Immunoglobulin G Fusion Protein, Recombinant
Sponsor:Sanofi AATD Inc.

Contact Research Centre

Colorectal cancer+4

Not recruiting

Study of IPN01194 for Adults with Advanced Solid Tumors, Including Melanoma, Head and Neck Cancer, Pancreatic Cancer, and Colorectal Cancer

InvestigationalNo placebo

Study of IPN01194 for Adults with Advanced Solid Tumors, Including Melanoma, Head and Neck Cancer, Pancreatic Cancer, and Colorectal Cancer

InvestigationalNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Ipn01194
Sponsor:Ipsen Pharma

Contact Research Centre

Hormone-refractory prostate cancer

Not recruiting

Study of EPI-7386 and Enzalutamide for Patients with Metastatic Castration-Resistant Prostate Cancer

Registered drugNo placebo

Study of EPI-7386 and Enzalutamide for Patients with Metastatic Castration-Resistant Prostate Cancer

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Enzalutamide
Sponsor:Essa Pharma Inc.

Contact Research Centre

Study on the Effects of Navitoclax and Ruxolitinib for Patients with Myelofibrosis

Not recruiting

Registered drugNo placebo

Study on the Effects of Navitoclax and Ruxolitinib for Patients with Myelofibrosis

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Navitoclax
Sponsor:AbbVie Deutschland GmbH & Co. KG

Contact Research Centre

Hepatocellular carcinoma

Not recruiting

Study on Advanced Liver Cancer: Evaluating Livmoniplimab and Budigalimab in Patients Without Prior Systemic Treatment

Registered drugNo placebo

Study on Advanced Liver Cancer: Evaluating Livmoniplimab and Budigalimab in Patients Without Prior Systemic Treatment

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Atezolizumab
Sponsor:AbbVie Deutschland GmbH & Co. KG

Contact Research Centre

Hepatocellular carcinoma

Not recruiting

Study of Nivolumab, Relatlimab and Bevacizumab combination for patients with untreated advanced or metastatic liver cancer (hepatocellular carcinoma)

Registered drug

Study of Nivolumab, Relatlimab and Bevacizumab combination for patients with untreated advanced or metastatic liver cancer (hepatocellular carcinoma)

Registered drug

Spain

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Bristol Myers Squibb International Corporation

Contact Research Centre

Influenza

Not recruiting

Study of intravenous zanamivir safety and effectiveness in infants under 6 months of age with complicated influenza infection

Registered drugNo placebo

Study of intravenous zanamivir safety and effectiveness in infants under 6 months of age with complicated influenza infection

Registered drugNo placebo

Spain

Participants:0–17 years
Substances:Zanamivir
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Multiple sclerosis

Not recruiting

Study on the Effects of SAR443820 and Gadobutrol in Patients with Multiple Sclerosis

Registered drug

Study on the Effects of SAR443820 and Gadobutrol in Patients with Multiple Sclerosis

Registered drug

Spain

Participants:18–64 years
Substances:Gadobutrol
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Other cities in Spain

The busiest research cities in the country

All 218 cities in Spain

Clinical research in Madrid

What the registry says about research in the country

01 Autoimmune and Inflammatory Conditions

Investigating novel treatments for cutaneous lupus erythematosus and immune thrombocytopenia, with studies evaluating new therapeutic approaches to manage these challenging conditions.

Lupus skin manifestations
Platelet disorders
Immune system regulation

Research focuses on improving treatment outcomes and quality of life for patients with autoimmune disorders.

02 Metabolic and Endocrine Disorders

Clinical trials examining innovative therapies for Type 1 Diabetes in combination with weight management, targeting both glycemic control and obesity-related complications.

Diabetes management
Weight control
Metabolic health

Studies aim to develop comprehensive treatment approaches for complex metabolic conditions.

03 Neurological Conditions

Breakthrough research in multiple sclerosis and acute ischemic stroke, exploring new therapeutic options for both pediatric and adult populations.

MS treatment in young patients
Stroke intervention
Neurological recovery

Focus on developing targeted treatments to improve neurological outcomes and patient care.

04 Infectious Disease Prevention

Comprehensive vaccine studies targeting respiratory syncytial virus, influenza, and herpes zoster, with particular attention to vulnerable populations.

Vaccine development
Immune response
Prevention strategies

Research aims to enhance protection against common and serious infectious diseases.

05 Oncology Research

Innovative studies in mantle cell lymphoma and bladder cancer, exploring combination therapies and targeted treatments to improve patient outcomes.

Lymphoma treatment
Bladder cancer therapy
Immunotherapy approaches

Focus on developing more effective and personalized cancer treatments.

Back to Spain All countries